Skip to content

Our mission is to discover and develop biomarkers for precision medicine using single-cell data and Artificial Intelligence.

About us

“True precision medicine through single-cell science.”

Our new and emerging analytical device produces rich data-sets by measuring hundreds of parameters from millions of individual cells. The resulting single-cell data holds the information needed for early disease detection, but it requires sophisticated and innovative computational approaches in order to extract the relevant information.

We are addressing this problem by developing artificial intelligence (AI) software for single-cell data analysis. The underlying best-in-class algorithms allow us to associate patterns in single-cell data with disease status.

We provide a powerful software solution (ScaiVision), unifying our AI technology for the global medical community and delivering it to those working in drug and diagnostic R&D.

Vision

To save lives by enabling precision medicine.

Our Team

Dr. Peter Nestorov

Founder & Chief Executive Officer

Peter holds a PhD in Genetics from the University of Basel and a degree in Biochemistry from the University of Tübingen. He has been working in the emerging single-cell analysis market since 2015 and this gave him the inspiration to start Scailyte as co-founder and CEO in 2017.

Dr. Sarah Carl

Director Data Science

Sarah holds a PhD in Genetics from the University of Cambridge. She worked as a bioinformatician at the Friedrich Miescher Institute in Basel, Switzerland, for four years before joining Scailyte. Sarah joined Scailyte as a data scientist in 2018 and has been recently promoted to become Director of Data Science.

Dr. Andrius Serva

Dr. Andrius Serva

Director Corporate Development

Andrius obtained a PhD in Systems Biology from Heidelberg University in Germany and continued as researcher in oncology at the German Cancer Research Center (DKFZ) in Heidelberg. After working for single-cell biotech Fluidigm, he joined Scailyte in 2019 and has been recently promoted to lead the Corporate Development team.

Anna Dimitrova, ACCA

Director Finance & Operations

Anna is an ACCA graduate with a Master’s degree in Finance and Banking from Sofia University. Previously, she worked as a finance manager in a fast growing company, auditor in KPMG and business consultant in PwC. Anna joined the Scailyte team in 2018.

Join the Scailyte team
Are you ready to help us transform biomedical research and healthcare? Please send us your CV, and your letter of motivation to join Scailyte, in an email to: careers@scailyte.com

Become part of something great.

To achieve our mission, we are looking for smart, passionate and dedicated individuals who share our values, by dreaming big, to join our growing, energetic and fun team. We offer flexible working schedules and home-office options

Join the Scailyte team
Are you ready to help us transform biomedical research and healthcare? Please send us your CV, and your letter of motivation to join Scailyte, in an email to: careers@scailyte.com

Recent News

Recent News

Scailyte and Volv Global announce strategic partnership to accelerate rare disease patient diagnosis

Two Artificial Intelligence (AI)-driven biomarker discovery companies Scailyte and Volv Global today

Read more

Recent News

Scailyte Quarterly Update, January 2021

Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

Recent News

ScaiVision® performs best-in-class at sample class prediction!

ScaiVision® v1.0.0 was released internally and benchmarked in a massive experiment, outperforming a

Read more

Recent News

Scailyte participates @ swissnex san francisco DEMO DAY!

Striving to internationalize and network, Scailyte participates and pitches at the swissnex Demo Day

Read more

Recent News

Scailyte Q3 2020 Update

Q3 2020 update on Scailyte's progress towards its mission to save millions of lives.

Read more

Recent News

ETH Industry E-Week 2020 features Scailyte with the headline: Using Artificial Intelligence to unlock the clinical potential of single-cell data.

As ETH- Spin-off Scailyte attends the 2020 Industry eWeek giving updates on the disease area focus,

Read more

Recent News

02 /04

Scailyte and Volv Global announce strategic partnership to accelerate rare disease patient diagnosis

Two Artificial Intelligence (AI)-driven biomarker discovery companies Scailyte and Volv Global today

Read more

Scailyte Quarterly Update, January 2021

Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

Recent News

03 /04

ScaiVision® performs best-in-class at sample class prediction!

ScaiVision® v1.0.0 was released internally and benchmarked in a massive experiment, outperforming a

Read more

Scailyte participates @ swissnex san francisco DEMO DAY!

Striving to internationalize and network, Scailyte participates and pitches at the swissnex Demo Day

Read more

Recent News

04 /04

Scailyte Q3 2020 Update

Q3 2020 update on Scailyte's progress towards its mission to save millions of lives.

Read more

ETH Industry E-Week 2020 features Scailyte with the headline: Using Artificial Intelligence to unlock the clinical potential of single-cell data.

As ETH- Spin-off Scailyte attends the 2020 Industry eWeek giving updates on the disease area focus,

Read more

Recent News

Dr. Peter Nestorov

Founder & Chief Executive Officer

Co-founder and Chief Executive Officer of Scailyte. He holds a PhD in genetics from the University of Basel and a degree in Biochemistry from the University of Tübingen.

During his PhD work, Dr. Nestorov pioneered the development and application of methods for single-cell analysis, which sparked his passion for this technology. In 2015, Dr. Nestorov joined Witec AG as Sales Specialist for single-cell and genomics technologies and successfully introduced the first commercial devices for single-cell analysis on the Swiss Life Science market. The interaction with biomedical researchers and the technological insight inspired Dr. Nestorov to start Scailyte and unlock the full clinical potential of single-cell data.

Mobile Menu Closed

Dr. Sarah Carl

Lead Data Scientist
is managing the Data Science division of Scailyte. She holds a PhD in Genetics and a Master’s degree in Developmental Biology from the University of Cambridge. Before joining Scailyte she was a post-doc and bioinformatician at the Friedrich Miescher Institute for Biomedical Research in Basel. At Scailyte she is leading the development of new applications and features of the internal data analysis platform, ScaiVision, and the data analysis of the clinical programmes.
Mobile Menu Closed

Stefan Almestrand

Director Clinical Development & Commercialization
Is Director of Corporate Development. He obtained a Master’s degree in Chemical and Biotech Engineering from the Royal Institute of Technology, Sweden. He started his career as a Project Manager at the Karolinska Institute in Sweden following a commercial career in business and medical affairs at various life Science, pharmaceutical and biotech companies such as Thermo Fisher Scientific, AstraZeneca and Fluidigm corporation. As the corporate development director at Scailyte, he works on the business strategy and commercial partnerships of the company.
Mobile Menu Closed

Anna Dimitrova, ACCA

Director Finance & Ops
Is the Director of Finance and Operations at Scailyte. She is an ACCA graduate with a Master’s degree in Finance and Banking from Sofia University. Before joining Scailyte she worked as Senior Audit Assistant at KPMG, Senior Business Consultant at PwC and as Finance Manager in a fast growing company in Bulgaria. At Scailyte she leads the finance, administration and internal operations of the company.
Mobile Menu Closed

Prof. Dr. Manfred Claassen

Founder & Chief Scientific Advisor AI & Single-Cell Analysis
Co-founder and Chief Scientific Advisor at Scailyte. He holds degrees in both Biochemistry and Computer Science from the University of Tübingen and a PhD in the design and validation of proteome measurements from the ETH Zurich. He continued his academic path as a postdoctoral researcher at Stanford University’s Artificial Intelligence Lab focusing on research in machine learning for high dimensional single-cell biology, he moved back to Switzerland as an Assistant Professor at the ETH. During this time, the idea of establishing a company specialising in digital healthcare was conceived. Dr. Claassen was instrumental in conceptualizing the new company. He is now professor for clinical bioinformatics at the University of Tübingen, Germany in parallel with his role as scientific consultant for Scailyte.
Mobile Menu Closed

Prof. Dr. Emmanuella Guenova

Clinical Advisor CTCL & Immunology
is a dermatologist, specialist in cutaneous lymphoma and laboratory diagnostics of skin diseases, and appointed professor at the Faculty of Biology and Medicine of the University of Lausanne. She is a senior physician-scientist, leading the specialized cutaneous lymphoma clinic at the Department of Dermatology of the Lausanne University Hospital (CHUV). Prof. Guenova is supporting Scailyte as a clinical advisor and principal investigator in our clinical development program for cutaneous T-cell lymphoma.
Mobile Menu Closed

Dr. Michael Stadler

received training in immunology and bioinformatics from the Universities of Lausanne and Geneva. He is a scientific advisor supporting Scailyte’s with the development of our data analytics platform. After postdoctoral studies in Bern and at the Massachusetts Institute of Technology (MIT), he joined the Friedrich Miescher Institute for Biomedical Research (FMI) Basel, where he is a staff scientist and leads the computational biology group.
Mobile Menu Closed

Pascal Winnen

CEO Hemex AG & Scailyte Board of Directors

Pascal is a co-founder and the CEO of HEMEX, a pharmaceutical, biotech and medical device consulting firm with offices in Switzerland, Germany and the USA. He holds a bachelor’s degree in Telecommunication Technologies from the University of Leuven (Belgium) and a master’s degree in Clinical Research from the Donau University in Krems (Austria). Pascal worked in various positions in the pharmaceutical and medtech industry.

From 2011 to 2015, Pascal worked for Finox Biotech, bringing one of the first biosimilar fertility treatments to the market in the EU and leading to the successful acquisition by Gedeon Richter for CHF 190 million. With his consulting firm HEMEX, Pascal has invested in multiple innovative life science startups, where he also advises on regulatory, clinical and marketing strategies, either as a senior consultant or as a board member.

Mobile Menu Closed

Dominique Mégret

Head of Swisscom Ventures & Scailyte Board of Directors
Dominique Mégret is head of Swisscom Ventures, which he started in 2007. He joined Swisscom in 2002 as head of the Group Strategy unit. Previously, Dominique Mégret was an entrepreneur in the United Kingdom, a strategy consultant in the European telecom industry and country manager for an IT company in Germany. He currently serves on the boards of Scailyte AG and Bloom SA. He is also an observer on the boards of Sophia Genetics and AVA Women.
Mobile Menu Closed